Rebecca is a senior associate in the Patents and Innovation Group. She advises clients on contentious patent matters and the commercialisation of intellectual property.
Rebecca has litigated in the High Court, Court of Appeal, and at the UK IPO. She regularly works on multi-jurisdictional cases and has particular experience advising clients in the life sciences and telecoms sectors. Prior to qualifying as a solicitor Rebecca worked in the life sciences sector, negotiating clinical trials and R&D related contracts.
von mehreren Autoren
Revocation of life sciences patents in the UPC
The Unified Patent Court (UPC), active since June 2023, is seeing strong uptake in pharma and biotech. Revocation decisions show a balanced 50:50 win rate for patentees and challengers. Key legal standards on novelty, obviousness, and inventive step are emerging, though some aspects remain unclear. Strategic use of the UPC offers broad enforcement, but revocation risks are higher for single-patent portfolios. Legal uncertainties, like the Bolar exemption, still need clarification.
von Lydia Birch und Rebecca Limer
4 von 5 Insights
von mehreren Autoren
von Dr. Benedikt Kohn, CIPP/E und Alexander Schmalenberger, LL.B.
von mehreren Autoren
von mehreren Autoren
von mehreren Autoren
von Oli Denne und Shane Gleghorn
von Irina Rebin
von Irina Rebin
von mehreren Autoren